AEON Biopharma is developing ABP-450, a botulinum toxin meant to be a biosimilar to Botox for therapeutic uses. AEON reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 1 | Lake Street | Maintained | Buy | |
| Aug 14 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How AEON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in AEON in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AEON is in one of them and how their past AEON trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AEON in an article yet. Here's the latest on the wider market.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company based in Aliso Viejo, California. It is developing ABP-450, a botulinum toxin intended to serve as a biosimilar to Botox for therapeutic medical uses rather than cosmetic ones. The product is still in development, and the company is working toward a regulatory filing in the United States. Its intended customers are physicians and patients who use botulinum toxin treatments for medical conditions.
- Headquarters
- Aliso Viejo, CA